GemPharmatech (688046) Mitigates Preclinical Risks in Neurotherapeutic Drug Development with Humanized TFRC Mouse Model
High Clinical Failure Rate and Limitations in Neurological R&D
The field of neurology faces a significant challenge: a clinical trial failure rate exceeding 90%, much higher than other disease areas. With the global preclinical contract research organization (CRO) market projected to grow rapidly to approximately USD 7.3 billion to 11.5 billion by 2026, mitigating risks in the early preclinical stage has become a critical priority. GemPharmatech (688046) addresses this by providing sophisticated mouse models, aiming to improve the success rate of drug development. Incomplete modeling of human disease mechanisms in the preclinical phase can lead to clinical failures, making their customized validation tools a crucial infrastructure for biotech R&D.
Validating Blood-Brain Barrier Permeability with Humanized TFRC Models
The blood-brain barrier (BBB) poses a major obstacle for developers of neurological therapeutics, blocking 98% of candidate molecules. GemPharmatech has developed a proprietary 'B6-hTFRC' model by replacing the mouse gene with the human transferrin receptor (TFRC/TFR1) gene using CRISPR/Cas9 technology. This model allows researchers to visualize and confirm in the preclinical stage whether therapeutic antibodies are safely delivered into the brain via receptor-mediated transcytosis (RMT). By demonstrating BBB permeability in a humanized environment early on, it significantly reduces clinical entry costs and failure rates.
Customized Disease Model Lineup for Alzheimer's and Parkinson's Disease
To accurately replicate the mechanisms of neurodegenerative diseases, GemPharmatech has established a lineup of genetically modified Alzheimer's disease (AD) and Parkinson's disease (PD) models. The FAD2T (APP/PS1), FAD3T (APP/PS1/Tau), and FAD4T models, which target Alzheimer's disease, rapidly replicate amyloid-beta (AΞ²) plaque deposition and the accumulation of phosphorylated tau protein. For Parkinson's disease research, they have developed 'B6-hSNCA-A53T' and 'B6-hSNCA-A53T/E46K' models that express human alpha-synuclein mutations, simulating motor dysfunction and protein aggregation. These models generate pathological responses comparable to those observed in clinical patients, ensuring the reliability of data in the development pipeline.
Securing Competitive Advantage through Preclinical CRO Partnerships
To compete with established large mouse model companies like Jackson Laboratory and Charles River Laboratories in the global market, GemPharmatech has expanded its scope beyond simple model sales to offer comprehensive preclinical CRO services. They provide all-in-one services that integrate advanced behavioral assessments, such as the Morris Water Maze and gait analysis, with histopathological analysis. This combination serves as a de-risking strategy, proactively eliminating uncertainties in biotech pipelines and facilitating rapid global licensing and technology transfer (L/O). The robust data generated in the preclinical phase significantly shortens clinical development timelines, enhancing market competitiveness in the long term.
The global market for neurodegenerative disease therapeutics is rapidly expanding due to an aging population, but with a clinical failure rate exceeding 90%, there is a critical need for solutions that mitigate risks in the preclinical stage. GemPharmatech (688046)'s humanized TFRC and FAD model platforms represent a powerful technological asset to compete with existing leading companies such as Jackson Laboratory in the global preclinical CRO market, which is valued at approximately USD 7.3 billion to 11.5 billion. This technology enables the early evaluation of BBB-penetrating candidates before clinical entry, directly contributing to reduced early-stage research costs and faster technology transfer (L/O) for biotech companies. In the medium to long term, it will significantly improve the preclinical success rate before the entry of highly complex neurological therapeutics into Phase 1/2 clinical trials, thereby streamlining the R&D process for new drug candidates and maximizing investment returns for venture capital (VC) firms in the CNS pipeline.